Affiris Ag

Affiris Cvd Gmbh

Guenther Staffler

Sylvia Brunner

Claudia Juno

Gergana Galabova

Gabriele Winsauer

Erika Bilcikova

Pola Linzmayer-Hirt

Birgit Schuh

Frank Mattner

Andreas Mairhofer

Bettina Wanko

Markus Windwarder

Christine Landlinger

Walter G Schmidt

Achim Schneeberger

Markus Mandler

Arne Von Bonin

Dorian Winter

Martina Lutterova

The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Peptide vaccines for hypercholesterolemia related diseases

Peptide vaccines usable for hypercholesterolemia related diseases

Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, that includes a peptide bound to a pharmaceutically acceptable carrier, wherein the peptide is QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9269-C1), or QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322) and wherein the IL-23 related disease is one or more of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies (ANCA-) associated vasculitides, neurodegenerative diseases, preferably M. Alzheimer or multiple sclerosis, atopic dermatitis, graft-versus-host disease, cancer, preferably Oesophagal carcinoma colorectal carcinoma, lung adenocarcinoma, small cell carcinoma, and squamous cell carcinoma of the oral cavity, especially psoriasis, neurodegenerative diseases or IBD.

IL-23-p19 vaccines

The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (X)KDXQLGX(SEQ ID No. 99), wherein Xis an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, Xis an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine. Xis (X4)nANISX5 (SEQ ID No. 100) or an N-terminal truncated fragment thereof consisting of 1 to 4 amino acid residues, Xis VVASQLR (SEQ ID No. 101) or an N-terminal truncated fragment thereof consisting of 1 to 6 amino acid residues, Xis an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glutamic acid, histidine, arginine, isoleucine, lysine, methionine, serine and threonine, m is 0 or 1, and n is 0 or 1, wherein said at least one peptide is coupled or fused to a carrier comprising at least one T-cell epitope.

Method of inhibiting C5a

The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.

Peptide vaccines against PCSK9

Treatments using a peptide and/or vaccine

Disclosed is a method for detecting aSyn-specific antibodies in a biological sample, comprising the following steps: &#x2014;contacting the sample with aSyn-comprising-aggregates and allowing the aSyn-specific antibodies to bind to the aSyn-comprising-aggregates, and &#x2014;detecting the aSyn-specific antibodies bound to the aSyn-comprising-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS).

Method for detecting aSyn-specific antibodies in a biological sample

The present invention relates to a immunogen comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID NO:9).

PCSK9 peptide combination vaccine and method of use

Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A&#x3b2;-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: &#x2014;contacting the sample with A&#x3b2;-aggregates or with particles having A&#x3b2;-aggregate like surfaces and allowing the A&#x3b2;-specific antibodies to bind to the A&#x3b2;-aggregates, and &#x2014;detecting the A&#x3b2;-specific antibodies bound to the A&#x3b2;-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A&#x3b2;-specific antibodies detected is compared with the amount in a sample of known AD status.

Method for diagnosing alzheimer's disease (AD)

Vaccine capable of inducing formation of antibodies directed to proprotein convertase subtilisin/kexin type 9 (PCSK9) in vivo

The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRANISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23) under the provision that the peptide fragment does not consist of amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG (SEQ ID No: 22).

Methods for inhibiting C5a with C5a peptides coupled or fused to a carrier protein

A vaccine or immunogenic composition comprising at least two fragments of proprotein convertase subtilisin/kexin type 9 (PCSK9) where one fragment contains at least 9 consecutive residues of residues 153 to 165 of PCSK9 and the other fragment contains at least 9 consecutive residues 209 to 222 of the PCSK9 (SEQ ID NO:9). Methods of treatment for hyperlipidemia, hypercholesterolemia, and atherosclerosis involving administering this vaccine.

Growing community of inventors

Vienna, Austria

Guenther Staffler